MedTrace Logo

Alprostadil in Maculopathy Study (AIMS)

NCT00619229 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-10-27

Study results available
· View outcomes & findings →

Summary

Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration

Conditions

  • Macular Degeneration

Interventions

DRUG

Alprostadil (prostaglandin E1)

Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.

OTHER

Placebo

Placebo/d i.v. for 15 days

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619229 on ClinicalTrials.gov